Wednesday, July 8, 2026

Patent intelligence · US

US 11639359

Bryoid compositions, methods of making and use thereof

granted A61KA61K31/365A61PA61P25/00
Status granted
Pipeline programs 2
Years to expiry 17
Applicant portfolio 39
Patent details — US 11639359
Jurisdiction
US
Status
granted
Grant date
May 2, 2023
Expiration
Apr 27, 2043
Applicant
Aphios Corporation
Claims
3
CPC classes
A61K, A61K31/365, A61P, A61P25/00
View on Google Patents ↗

Quick answer

US 11639359 (Bryoid compositions, methods of making and use thereof) is held by Aphios Corporation. Status: granted. Granted May 2, 2023. Expires Apr 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Aphios Corporation
Grant date
Expiration
Claims
3
CPC classes
A61K, A61K31/365, A61P, A61P25/00, A61P25/14, A61P25/16

More from Aphios Corporation

Related pharmaceutical patents in our USPTO index.

  1. US 11926828

    Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

    Phio Pharmaceuticals Corp. · Expires Mar 7, 2044

    granted
  2. US 11584933

    RNA interference in ocular indications

    Phio Pharmaceuticals Corp. · Expires Feb 16, 2043

    granted
  3. US 11396654

    Neutral nanotransporters

    Phio Pharmaceuticals Corp. · Expires Jul 21, 2042

    granted
  4. US 11279934

    Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

    Phio Pharmaceuticals Corp. · Expires Mar 17, 2042

    granted
  5. US 11254940

    Inhibition of MAP4K4 through RNAi

    Phio Pharmaceuticals Corp. · Expires Feb 17, 2042

    granted
  6. US 11234932

    Combination HIV therapeutic

    Aphios Corporation · Expires Jan 27, 2042

    granted
  7. US 11118178

    Reduced size self-delivering RNAI compounds

    Phio Pharmaceuticals Corp. · Expires Sep 9, 2041

    granted

Frequently asked questions

What is US patent 11639359?

US 11639359 (Bryoid compositions, methods of making and use thereof) is held by Aphios Corporation. Status: granted. Granted May 2, 2023. Expires Apr 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11639359?

Aphios Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.

When does US 11639359 expire?

Our index shows an expiration date of Apr 27, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.